Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)

We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Ramos, Juan C., Sparano, Joseph A., Rudek, Michelle A., Moore, Page C., Cesarman, Ethel, Reid, Erin G., Henry, David, Ratner, Lee, Aboulafia, David, Lee, Jeanette Y., Ambinder, Richard F., Mitsuyasu, Ronald, Noy, Ariela
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697160/
https://ncbi.nlm.nih.gov/pubmed/29426719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.01.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados